Multiple Myeloma Immunophenotype Related to Chromosomal Abnormalities Used in Risk Assessment

Diagnostics (Basel). 2022 Aug 24;12(9):2049. doi: 10.3390/diagnostics12092049.

Abstract

(1) Background: At diagnosis, multiplemyeloma risk estimation includes disease burden, end-organ damage, and biomarkers, with increasing emphasis on genetic abnormalities. Multicolor flow cytometry (MFC) is not always considered in risk estimation. We demonstrate associations found between genetic abnormalities and antigen expression of plasma cells measured by MFC. (2) Methods: Single nucleotide polymorphism microarray (SNP-A) karyotyping as well as MFC using standardized next-generation flow (NGF) panels and instrument settings were performed from bone marrow aspirates at the time of diagnosis. (3) Results: We uncovered specific immunophenotype features related to different genetic risk factors. Specifically, we found higher malignant/normal plasma cell ratio and lower expression of CD27, CD38, CD45, CD56, CD117 and CD138 in higher-risk genetic groups or risk categories.

Keywords: flow cytometry; immunophenotype; multiple myeloma; risk assessment; single nucleotide polymorphism microarray.

Grants and funding

This research received no external funding.